Newly diagnosed adult with Ph1 positive acute lymphoblastic leukemia
Conditions
Interventions
Phase 1 Induction:Induction Therapy: all patients recieve the same induction therapy with Imatinib,vindesine and dexamethasone
Phase 2: Intensify Chemotherapy :Patients achieve CR, will recieve 3 courses of intensified chemotherapy
Phase 3 Allo-SCT Group :Patient as a candidate for Allo stem cell transplantation will receive transplantation as soon as he/she complete intensify chemotherapy. Otherwise, chemotherapy as maintenanc
Phase 3 Maintenance Group :Maintenance Therapy: imatinib plus oncovin and dexamethasone, and intrathecal prevention of CNS leukemia.Maintennance therapy will continue for 2 years.
Sponsors
Department of Hematology of West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
15 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed acute lymphoblastic leukemia with positive BCR/ABL fusion gene or positive Ph1 chromosome; 2. HBV surface antigen negative, or HBV-DNA<1*10^3 copy/ml for the HBsAg positive patients; 3. Total bilirubin <2 times of upper limit, ALT <3 times of upper limit, AST <3 times of upper limit.
Exclusion criteria
Exclusion criteria: 1. ECOG>2; 2. previous history of small molecular target drug for BCR/ABL gene(e.g. Imatinib, Dasatinib etc); 3. previous history of allo stem cell transplantation; 4. severe underlying disease of vital organs(e.g. heart, lung, liver, kidney, pancrea); 5. active GI or Urinary Hemorrhage; 6. previous history of chronic myelogenous leukemia; 7. complicated other malignancies, not including cured cervix cancer; 8. woman with pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free survival;overall survival;CR rate; | — |
Countries
China
Contacts
Public ContactTing Liu
Outcome results
None listed